MilliporeSigma and Stelis Biopharma Open First Joint Bioprocess Scale-up Lab in India
- Joint lab provides end-to-end solutions from bioprocessdevelopment to manufacturing for pre-clinical, clinical andcommercial supply
- Accelerates product availability for clinical trials with greaterreliability, cost effectiveness
- Offers seamless, robust transfer of optimized processes from small-scale R&D lab to large-scale commercial manufacturing
Billerica, Massachusetts, May 12, 2017 – MilliporeSigma today announced the opening of a new joint Process Scale-Up Lab in Bengaluru, India to provide end-to-end solutions from process development to scale-up manufacturing for pre-clinical, clinical and commercial supply.
“Both MilliporeSigma and Stelis bring technological expertise and an extensive bioprocess development and manufacturing portfolio that will help customers accelerate development of biopharmaceuticals for clinical trials and manufacturing with greater reliability and cost effectiveness,” said Udit Batra, CEO, MilliporeSigma.
The collaboration reinforces MilliporeSigma’s position as the premier supplier of process development and clinical state manufacturing solutions, materials and services needed for biologics production.
“In the biopharma space, where the process is the product, the Process Scale-Up Lab fulfils a critical need by offering clients a reliable process bridge between R&D and commercial scales,” said Joe Thomas, CEO of Stelis Biopharma. “The collaboration with MilliporeSigma completes the value proposition for CDMO customers by providing an end-to-end solution from process development and scale-up through to manufacturing for pre-clinical, clinical and commercial supply.”
The lab, located at the Stelis Biopharma R&D Facility in Bengaluru, was built as a centre of excellence for process scale-up and manufacturing services. The collaboration brings together Stelis’ end-to-end capabilities in high-yield bioprocess development from cell line to commercial manufacturing scale and MilliporeSigma’s industry leading technological expertise in bioprocessing.
The lab and a soon-to-be-completed cGMP manufacturing facility will house MilliporeSigma’s portfolio of Mobius® bioprocessing equipment and single-use manufacturing components. MilliporeSigma will provide process know-how and application knowledge to help establish the single-use platform technologies at Stelis as part of the collaboration.
All Merck KGaA, Darmstadt, Germany, press releases are distributed by e-mail at the same time they become available on the EMD Group Website. In case you are a resident of the USA or Canada please go to www.emdgroup.com/subscribe to register again for your online subscription of this service as our newly introduced geo-targeting requires new links in the email. You may later change your selection or discontinue this service.
About Merck KGaA, Darmstadt, Germany
Merck KGaA, Darmstadt, Germany, is a leading science and technology company in healthcare, life science and performance materials. Around 50,000 employees work to further develop technologies that improve and enhance life – from biopharmaceutical therapies to treat cancer or multiple sclerosis, cutting-edge systems for scientific research and production, to liquid crystals for smartphones and LCD televisions. In 2016, Merck KGaA, Darmstadt, Germany, generated sales of € 15.0 billion in 66 countries.
Founded in 1668, Merck KGaA, Darmstadt, Germany, is the world's oldest pharmaceutical and chemical company. The founding family remains the majority owner of the publicly listed corporate group. Merck KGaA, Darmstadt, Germany, holds the global rights to the „Merck” name and brand. The only exceptions are the United States and Canada, where the company operates as EMD Serono, MilliporeSigma and EMD Performance Materials.
AI-driven experimentation planner BayBE (Bayesian Back End) by us and Acceleration Consortium is available open-source on GitHub